Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short-term Investments Total Current Liabilities Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

CorMedix (CRMD) Convertible Debt (2018 - 2019)

CorMedix has reported Convertible Debt over the past 4 years, most recently at $6.7 million for Q2 2019.

Quarterly results put Convertible Debt at $6.7 million for Q2 2019, changed N/A from a year ago — trailing twelve months through Jun 2019 was $6.7 million (changed N/A YoY), and the annual figure for FY2018 was $6.1 million, changed.
Convertible Debt reached $6.7 million in Q2 2019 per CRMD's latest filing, up from $6.4 million in the prior quarter.
Across five years, Convertible Debt topped out at $6.7 million in Q2 2019 and bottomed at $6.1 million in Q4 2018.